Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Auxilium has signed an agreement with Paladin Labs for the Canadian distribution rights to Testim, its testosterone gel, indicated for the treatment of patients with hypogonadism.
Subscribe to our email newsletter
Hypogonadism is defined as reduced or absent secretion of testosterone which can lead to symptoms such as loss of libido, adverse changes in body composition, irritability and poor concentration.
“This agreement enables us to bring our innovative testosterone replacement product to Canadian patients and to continue to expand the reach of our Testim franchise outside the US,” said Armando Anido, CEO and president of Auxilium.
Under the agreement, Auxilium will be responsible for manufacturing and supplying Testim to Paladin. Paladin will be responsible for all sales, marketing and distribution activities in Canada. Financial details of the agreement were not disclosed.
Testim is approved for sale in 15 countries outside the US. Auxilium and Bayer of Canada recently agreed to mutually terminate their distribution agreement for Testim in Canada.